Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment

Evidence on pasireotide LAR's cost-effectiveness versus pegvisomant regimens remains inconclusive. Although two studies indicated that pegvisomant is more cost-effective, the study with the highest methodological credibility found that pasireotide LAR is a cost-effective alternative.